Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker.

OBJECTIVES--This study examines the acute effects of two differing beta adrenergic blocking agents (metoprolol and a third generation vasodilating beta blocker) on plasma concentrations of atrial natriuretic factor (ANF), brain (ventricular) natriuretic factor (BNF), and haemodynamic variables in patients with heart failure. SETTING--University teaching hospital. METHODS--20 patients with impaired left ventricular systolic function [ejection fraction 32 (SEM 2.3)%] were randomised in a double blind manner to receive either oral metoprolol 6.25 mg twice daily or celiprolol 25 mg daily. Haemodynamic variables were evaluated by Swan-Ganz pulmonary artery catheter over 24 hours. ANF and BNF concentrations were measured at baseline, 5 h, and 24 h by radioimmunoassay. RESULTS--At baseline ANF and BNF concentrations were considerably raised compared to the normal range. Treatment with metoprolol caused ANF to rise further to 147% of the basal level at 5 h (P = 0.017) and 112% at 24 h (P = 0.029). This was associated with a small but non-significant rise in pulmonary capillary wedge pressure. Cardiac output and systemic vascular resistance were unchanged at 24 h. In contrast, after celiprolol ANF fell to 90% of basal levels at 5 h and to 74% of basal level at 24 h (P = 0.019), associated with a small but non-significant fall in pulmonary capillary wedge pressure [-3.3 (2.7) mm Hg] and systemic vascular resistance, and rise in cardiac output from 3.2 (0.2) to 4.0 (0.4) l/min (P = 0.04). BNF concentrations rose to 112% of baseline at 5 h (P = 0.09) after metoprolol but fell slightly, to 91% of baseline values, after celiprolol (NS). CONCLUSIONS--Metoprolol, even in very low doses (6.25 mg), produced a rise in ANF and BNF, although minimal haemodynamic changes were detected. In contrast, a vasodilating beta blocker was associated with a significant fall in ANF and BNF and a small rise in cardiac output. This study confirms both the advantages of vasodilating beta blockers over metoprolol for initial treatment of heart failure and the usefulness of ANF and BNF measurements for the assessment of drug effects in heart failure compared to traditional haemodynamic measurements.

[1]  R. Norris,et al.  Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). , 1995, The American journal of cardiology.

[2]  K. Nakao,et al.  Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. , 1994, British heart journal.

[3]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[4]  A. Daul,et al.  Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. , 1994, Journal of the American College of Cardiology.

[5]  R. Doughty,et al.  Beta-blockers in heart failure: promising or proved? , 1994, Journal of the American College of Cardiology.

[6]  A R Jayaweera,et al.  Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy? , 1993, Circulation.

[7]  W. Edwards,et al.  Natriuretic peptide system in human heart failure. , 1993, Circulation.

[8]  P. Serruys,et al.  Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire. Limitations for the application of the continuity equation in the assessment of stenosis severity. , 1993, The American journal of cardiology.

[9]  A. Struthers,et al.  Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction , 1993, The Lancet.

[10]  M. Brown,et al.  Beta adrenoreceptor subtype cross regulation in the human heart. , 1993, British heart journal.

[11]  M. Bristow Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. , 1993, The American journal of cardiology.

[12]  H. Ikram,et al.  Therapeutic controversies with use of beta-adrenoceptor blockade in heart failure. , 1993, The American journal of cardiology.

[13]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[14]  A. Lenarda,et al.  Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .

[15]  R. Candinas,et al.  Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. , 1990, Circulation.

[16]  G. Mancia,et al.  Sympathetic activation in congestive heart failure. , 1990, European heart journal.

[17]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[18]  P. Erne,et al.  Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. , 1986, The New England journal of medicine.

[19]  A. Mark,et al.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. , 1986, Circulation.

[20]  M. Packer,et al.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.

[21]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[22]  E. Varnauskas,et al.  Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. , 1975, British heart journal.

[23]  S. Stephen Unwanted effects of propranolol. , 1966, The American journal of cardiology.

[24]  H. Burchell,et al.  Focal myocarditis associated with pheochromocytoma. , 1966, The New England journal of medicine.

[25]  R. Lefkowitz,et al.  Enhanced Myocardial Function inTransgenic Mice Overexpressing theP2-Adrenergic Receptor , 1994 .

[26]  Vincent T.F. Yeung,et al.  Natriuretic Peptide Receptors , 1993 .

[27]  I. Balažovjech,et al.  The effect of short-term celiprolol therapy on platelet function in essential hypertension. , 1993, Cardiology.

[28]  B. Prichard β-blocking agents with vasodilating action , 1992 .

[29]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.